BlueWillow Biologics® is a clinical-stage, privately-held biopharmaceutical company. We’re focused on developing and commercializing prophylactic and therapeutic vaccines using our patented NanoVax® platform. The NanoVax platform employs a novel oil-in-water nanoemulsion adjuvant that is effective when administered intranasally, intramuscularly and topically, and can elicit both mucosal and systemic immunity creating “bouncers at the door” to keep infections out and direct the immune system to respond properly to pathogens or allergens. Studies point to increased protection against some of the world’s most challenging respiratory and sexually transmitted diseases, and most concerning food allergens.
MichBio interviews BlueWillow Biologics CEO Dave Peralta on the use of intranasal vaccine in fighting respiratory and sexually transmitted infections. The podcast is also available on SoundCloud.
BlueWillow’s intranasal vaccine technology has demonstrated safety and immunogenicity in Phase 1 clinical studies for seasonal influenza. Several other programs have advanced through successful challenge studies in primary animal models. Choose a pathogen and click for details on our research results and partnering information.